Caliber Wealth Management LLC KS Decreases Stake in Merck & Co., Inc. $MRK

Key Points

• Caliber Wealth Management LLC KS has significantly reduced its stake in Merck & Co., Inc. by 73.1%, now holding only 8,269 shares valued at approximately $655,000.
• Despite the decrease in holdings by some investors, other institutional investors, such as Parcion Private Wealth LLC and Steel Grove Capital Advisors LLC, have increased their stakes in Merck during the same period.
• Merck & Co., Inc. reported $2.13 earnings per share for the last quarter, exceeding analysts' estimates, while setting a fiscal year 2025 EPS guidance of 8.870-8.970.

Caliber Wealth Management LLC KS decreased its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 73.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,269 shares of the company's stock after selling 22,499 shares during the quarter. Caliber Wealth Management LLC KS's holdings in Merck & Co., Inc. were worth $655,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Rehmann Capital Advisory Group grew its stake in shares of Merck & Co., Inc. by 1.2% during the 2nd quarter. Rehmann Capital Advisory Group now owns 33,204 shares of the company's stock worth $2,629,000 after purchasing an additional 409 shares during the period. Parcion Private Wealth LLC boosted its holdings in Merck & Co., Inc. by 9.3% during the second quarter. Parcion Private Wealth LLC now owns 21,997 shares of the company's stock worth $1,741,000 after buying an additional 1,863 shares in the last quarter. Steel Grove Capital Advisors LLC increased its holdings in Merck & Co., Inc. by 655.1% in the second quarter. Steel Grove Capital Advisors LLC now owns 24,374 shares of the company's stock valued at $1,929,000 after buying an additional 21,146 shares in the last quarter. Patten Group Inc. increased its holdings in Merck & Co., Inc. by 0.5% in the second quarter. Patten Group Inc. now owns 30,913 shares of the company's stock valued at $2,447,000 after buying an additional 140 shares in the last quarter. Finally, Members Trust Co increased its holdings in Merck & Co., Inc. by 9.6% in the second quarter. Members Trust Co now owns 5,712 shares of the company's stock valued at $452,000 after buying an additional 499 shares in the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $87.60 on Thursday. The firm has a 50 day simple moving average of $84.28 and a 200-day simple moving average of $81.43. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $107.36. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17. The stock has a market cap of $218.81 billion, a price-to-earnings ratio of 13.50, a price-to-earnings-growth ratio of 0.96 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, topping analysts' consensus estimates of $2.03 by $0.10. The firm had revenue of $15.81 billion during the quarter, compared to analysts' expectations of $15.92 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

Analyst Upgrades and Downgrades

MRK has been the subject of a number of recent analyst reports. Morgan Stanley cut their price objective on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an "equal weight" rating for the company in a report on Thursday, July 10th. Weiss Ratings reissued a "hold (c-)" rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Citigroup began coverage on shares of Merck & Co., Inc. in a research note on Monday, October 13th. They set a "neutral" rating and a $95.00 target price for the company. Berenberg Bank cut shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and cut their target price for the stock from $100.00 to $90.00 in a research note on Wednesday, September 17th. Finally, Wells Fargo & Company cut their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $104.33.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.